ArticleJMIR mental health2023
Efficacy of a Smartphone App in Enhancing Medication Adherence and Accuracy in Individuals With Schizophrenia During the COVID-19 Pandemic: Randomized Controlled Trial.
Article in JMIR mental health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05892120 (The Effectiveness of a Smartphone App on Medication Adherence and Psychotic Symptoms and Cognitive Functions in Patients With Schizophrenia), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effectiveness of a Smartphone App on Medication Adherence and Psychotic Symptoms and Cognitive Functions in Patients With Schizophrenia
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- AI-powered cognitive remediation for schizophrenia: a psychologist's lens on evidence and scalability in India.Frontiers in psychology · 2026Pooled it
- Artificial intelligence in mental health care: a systematic review of diagnosis, monitoring, and intervention applications.Psychological medicine · 2025Pooled it
- Application of artificial intelligence in schizophrenia rehabilitation management: a systematic scoping review.Translational psychiatry · 2026Article
- Smartphone Apps and Digital Tools for Managing Schizophrenia and Psychotic Disorders: A Clinical Review.Focus (American Psychiatric Publishing) · 2025Review
- The evolving field of digital mental health: current evidence and implementation issues for smartphone apps, generative artificial intelligence, and virtual reality.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Can artificial intelligence be the future solution to the enormous challenges and suffering caused by Schizophrenia?Schizophrenia (Heidelberg, Germany) · 2025Review
- Community Caregivers' Perspectives on Health IT Use for Children With Medical Complexity: Qualitative Interview Study.JMIR pediatrics and parenting · 2025Article
- Systematic review and meta-analysis of adverse events in clinical trials of mental health apps.NPJ digital medicine · 2024Article
- Exploration of Features of Mobile Applications for Medication Adherence in Asia: Narrative Review.Journal of medical Internet research · 2024Review
- Article
- Mobile-Based Medication Management Applications: A Scoping Review of Functional and Non-Functional Requirements.Healthcare technology lettersReview
- Views on the usability and usefulness of the PeerConnect app among Ontario public safety professionals.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor medication adherence or inaccuracy in taking prescribed medications plays an important role in the recurrence or worsening of psychiatric symptoms in patients with schizophrenia, and the COVID-19 pandemic impacted their medication adherence with exacerbated symptoms or relapse. The use of mobile health services increased during the COVID-19 pandemic, and their role in improving mental health is becoming clearer.
objectiveThis study aimed to explore the effectiveness of a smartphone app (MedAdhere) on medication adherence and accuracy among patients with schizophrenia and to measure their psychiatric symptoms and cognitive functions.
methodsIn this 12-week experimental study, participants were provided interventions with the MedAdhere app, and data were collected between June 2021 and September 2022. A total of 105 participants were randomly assigned to either the experimental or control groups. We used the Positive and Negative Syndrome Scale and Mini-Mental State Examination to measure the participants' psychiatric symptoms and cognitive functions. Generalized estimating equations were used for data analysis.
resultsA total of 94 participants met the inclusion criteria and completed the protocol, and the medication adherence rate of the experimental group was 94.72% (2785/2940) during the intervention. Psychotic symptoms (positive, negative, and general psychopathology symptoms) and cognitive functions (memory, language, and executive function) were significantly improved in the experimental group compared to the control group after the intervention.
conclusionsThe MedAdhere app effectively and significantly improved medication adherence and, thereby, the psychiatric symptoms of patients with schizophrenia. This artificial intelligence assisted app could be extended to all patients who need to be reminded to take medication on schedule.
trial registrationClinicalTrials.gov NCT05892120; https://clinicaltrials.gov/study/NCT05892120.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.